A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors (NCT06515613)
A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).
Who can join: Review the eligibility criteria below.
Location: University of Arkansas Winthrop P. Rockefeller Cancer Institute — Little Rock, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- University of Arkansas Winthrop P. Rockefeller Cancer Institute — Little Rock, Arkansas
- Precision NextGen Oncology & Research Center — Beverly Hills, California
- SCRI at Denver Health — Denver, Colorado
- Dana-Farber Cancer Institute — Boston, Massachusetts
- John Theurer Cancer Center — Hackensack, New Jersey
- Memorial Sloan Kettering Cancer Center — New York, New York
- Duke Cancer Institute — Durham, North Carolina
- Gabrail Cancer Center — Canton, Ohio
- Providence Cancer Institute of Oregon — Portland, Oregon
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- Women & Infants Hospital of Rhode Island — Providence, Rhode Island
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
- SCRI at Mary Crowley — Dallas, Texas
- University College London Hospital — London,
📞 Contact the Study Coordinator
Phone: (267) 225-7416
Email: cntx-ctim76-101@contexttherapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Platinum-resistant Ovarian Cancer
- Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) — Phoenix, Arizona
- Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer — Anchorage, Alaska
- A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer — El Segundo, California
- Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer — Boston, Massachusetts
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) — Mobile, Alabama
Explore by condition: All Platinum-resistant Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.